CANCER RESEARCH UK scientists have developed a system to identify faulty or missing genes that could prevent specific chemotherapy regimes from working. This opens the doors for targeted breast cancer treatment, according to research published in the Lancet Oncology today (Monday).
An international team of scientists led by Cancer Research UK's London Research Institute together with the Technical University of Denmark developed a bespoke method to scan 829 genes involved in response to a breast cancer drug, in breast cancer tumour cells. They selected those which if missing or faulty would prevent a chemotherapy drug called paclitaxel, from working effectively in patients with breast cancer.
Taxanes block the growth of cancer cells by stopping cell division. The group includes paclitaxel (Taxol) and docetaxel (Taxotere) which is given to patients with breast cancer before surgery.
The team used a technique called RNA interference to delete each of the 829 genes, one at time in cancer cells, to explore how well paclitaxel worked in tumour cells if one particular gene was not working normally.
They narrowed the search down to find six genes which if faulty prevent paclitaxel from working effectively in breast cancer cells in the laboratory. They then showed in patients that these same six genes in breast cancer cells could be used to predict which of them will derive the most benefit from paclitaxel before they are exposed to treatment.
Lead author Dr Charles Swanton, head of translational cancer therapeutics at Cancer Research UK's London Research Institute, said: "A great challenge in cancer medicine is determining which patients will benefit from particular cancer drugs and it is hoped that this research is a step towards more rapid developments in this type of personalised medicine."
"Since the whole human genome was sequenced, scientists have been trying to understand the role of each of the 21,000 genes contained within it. Our research shows it is now possible to rapidly pinpoint genes which prevent cancer cells from being destroyed by anti-cancer drugs and use these same genes to predict which patients will benefit from specific types of treatment."
More than 45,500 women are diagnosed with breast cancer in the UK each year - and it is estimated that around 15 per cent of these women will be prescribed paclitaxel. The researchers estimate from this small study that they could spare the prescription of less effective treatment to half of patients currently receiving this drug.
This research paves the way for further studies to determine if the technique can be developed into a simple diagnostic test to be given to patients to help inform doctors about whether or not to prescribe paclitaxel.